MedTrace Logo

I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy

NCT05537922 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2200

Last updated 2023-01-06

No results posted yet for this study

Summary

I3LUNG is an international project aiming to develop a medical device to predict immunotherapy efficacy for NSCLC patients using the integration of multisource data (real word and multi-omics data). This objective will be reached through a retrospective - setting up a transnational platform of available data from 2000 patients - and a prospective - multi-omics prospective data collection in 200 NSCLS patients - study phase.

The retrospective cohort will be used to perform a preliminary knowledge extraction phase and to build a retrospective predictive model for IO (R-Model), that will be used in the prospective study phase to create a first version of the PDSS tool, an AI-based tool to provide an easy and ready-to-use access to predictive models, increasing care appropriateness, reducing the negative impacts of prolonged and toxic treatments on wellbeing and healthcare costs.

The prospective part of the project includes the collection and the analysis of multi-OMICs data from a multicentric prospective cohort of about 200 patients. This cohort will be used to validate the results obtained from the retrospective model through the creation of a new model (P-Model), which will be used to create the final PDSS tool.

Conditions

  • Non Small Cell Lung Cancer
  • Lung Cancer Metastatic
  • Lung Cancer, Nonsmall Cell
  • Lung Adenocarcinoma

Sponsors & Collaborators

  • Vall d'Hebron Institute of Oncology

    collaborator OTHER

  • Shaare Zedek Medical Center

    collaborator OTHER

  • LungenClinic Grosshansdorf

    collaborator OTHER

  • Metropolitan Hospital, Athens

    collaborator UNKNOWN

  • University of Chicago

    collaborator OTHER

  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-01
Primary Completion
2025-10-01
Completion
2027-10-01

Countries

  • United States
  • Greece
  • Israel
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05537922 on ClinicalTrials.gov